MARKET

OPK

OPK

OPKO Health
NASDAQ

Real-time Quotes | Nasdaq Last Sale

4.130
-0.070
-1.67%
After Hours: 4.110 -0.02 -0.48% 17:55 04/20 EDT
OPEN
4.170
PREV CLOSE
4.200
HIGH
4.200
LOW
4.050
VOLUME
4.61M
TURNOVER
--
52 WEEK HIGH
6.47
52 WEEK LOW
1.680
MARKET CAP
2.77B
P/E (TTM)
86.58
1D
5D
1M
3M
1Y
5Y
Global Smart Inhalers Market (2020 to 2025) - by Components, Product, Application, Distribution Channel, End-use and Geography
, /PRNewswire/ -- The report has been added to offering.
PR Newswire - PRF · 5h ago
Prostate Cancer Diagnostics Market Growth, Trends, Global Industry Report and Forecast 2020 - 2027
The global Prostate Cancer Diagnostics market size is expected to be worth around US$ 7.65 billion by 2027. Major drivers include increasing government initiatives, high prevalence of prostate cancer, and technological advancements in confirmatory diagnost...
Market Stats News · 18h ago
Esoteric Testing Market Size, Industry Report by Share, Growth, Key Regions, Segments, Trends, Technology and Forecast till 2028
Apr 19, 2021 (Heraldkeepers) -- Market Research Engine has published a new report titled as "Esoteric Testing Market by Technology (Mass Spectrometry, CLIA,...
Heraldkeepers · 1d ago
Insights on the Solid Tumor Testing Global Market to 2030 - Focus on Technology, Cancer Type, Application, End-user and Competitive Landscape
Dublin, April 19, Apr 19, 2021 (GLOBE NEWSWIRE via COMTEX) -- Dublin, April 19, 2021 (GLOBE NEWSWIRE) -- The "Global Solid Tumor Testing Market 2019-2030:...
GlobeNewswire · 1d ago
Human Growth Hormones Deficiency (GHD) Drugs Market Outlook, Industry Analysis and Prospect 2021-2025 | Says Kenneth Research
AmericaNewsHour · 1d ago
Respiratory Inhalers Market Report 2021-2031
GlobeNewswire · 5d ago
Clinical Laboratory Tests Market Report 2021-2031
New York, April 15, Apr 15, 2021 (GLOBE NEWSWIRE via COMTEX) -- New York, April 15, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the...
GlobeNewswire · 5d ago
Esoteric Testing Market 2021 Global Technology, Development, Industry Share, Size, Growth, Trends and COVID-19 Impact Analysis 2027
Apr 15, 2021 (Heraldkeepers) -- The Esoteric Testing Market is expected to exceed more than US$ 35 Billion by 2024 at a CAGR of 12% in the given forecast...
Heraldkeepers · 5d ago
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of OPK. Analyze the recent business situations of OPKO Health through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 5 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average OPK stock price target is 8.25 with a high estimate of 10.00 and a low estimate of 6.50.
EPS
Institutional Holdings
Institutions: 351
Institutional Holdings: 196.98M
% Owned: 29.40%
Shares Outstanding: 670.04M
TypeInstitutionsShares
Increased
61
5.92M
New
49
6.44M
Decreased
70
13.86M
Sold Out
21
5.83M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
+0.59%
Pharmaceuticals & Medical Research
+0.33%
Key Executives
Chairman/Chief Executive Officer/Director
Phillip Frost
Vice Chairman/Chief Technology Officer/Director
Jane Hsiao
Chief Financial Officer/Senior Vice President/Chief Accounting Officer/Treasurer
Adam Logal
Corporate Executive/Director
Jon Cohen
Senior Vice President
Akhtar Ashfaq
Corporate Executive
Charles Bishop
Other
Thomas Nusbickel
Corporate Executive
Tony Cruz
Corporate Executive
Geoff Monk
Executive Vice President/Director
Steven Rubin
Independent Director
Robert Fishel
Independent Director
Anthony Japour
Independent Director
Richard Krasno
Independent Director
Prem Lachman
Independent Director
Richard Lerner
Independent Director
Roger Medel
Independent Director
John Paganelli
Independent Director
Richard Pfenniger
Independent Director
Alice Yu
No Data
  • All
  • Financials
  • Insiders
More
About OPK
OPKO Health, Inc. is a healthcare company. Its segments include Pharmaceutical, Diagnostics and Corporate. Pharmaceutical consists of the pharmaceutical operations in Chile, Mexico, Ireland, Israel and Spain and its pharmaceutical research and development operations. Diagnostics consists of the clinical laboratory operations in Bio-Reference Laboratories (Bio-Reference) and its point-of-care operations. Through Bio-Reference, it operates laboratory divisions, such as Bio-Reference, GenPath (Oncology), GenPath (Women's Health), GeneDx and Laboratorio Bueno Salud. As of December 31, 2016, it had one commercial stage pharmaceutical product and several pharmaceutical compounds and technologies in various stages of research and development for a range of indications and conditions, including Renal Products, Biologics, hGH-CTP, Factor VII, Oxyntomodulin, active pharmaceutical ingredients, Oligonucleotide Therapeutics, NK-1 Program, Asthma and chronic obstructive pulmonary disease.

Webull offers kinds of Opko Health Inc. stock information, including NASDAQ:OPK real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, OPK stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading OPK stock methods without spending real money on the virtual paper trading platform.